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Abstract
Background: The most common cause of ocular morbidity in developed countries is dry eye,
many cases of which are due to lacrimal insufficiency. Dry eye affects approximately 10 million in
the United States., most of whom are women. In the U.S. alone, an estimated 2 million Sjögren's
syndrome patients have dysfunctional lacrimal glands and severe dry eye, and there is no
satisfactory treatment. These patients would benefit if their lacrimal tissue function could be
restored.
Methods: The effect of adenovirus-mediated transfer of tumor necrosis factor (TNF)-α inhibitor
gene on induced autoimmune dacryoadenitis was evaluated in a rabbit model. Soluble transgene
protein was detected in tears by ELISA for 7 days following transduction.
Results: Two weeks after induction of disease with activated lymphocytes, tear production, as
determined by Schirmer testing, was reduced by about 40%, while tear film stability, as measured
by tear breakup time (BUT), declined by 43%. Adenovirus-mediated gene therapy using
AdTNFRp55-Ig given 2 weeks after disease induction, resulted in the return of tear production to
normal levels by week 4. In the treated disease group, tear BUT improved significantly by week 4.
Rose bengal scores, an indicator of corneal surface defects, increased after disease induction and
declined after gene therapy. In the lacrimal gland, the CD4 to CD8 T cell ratio was 4:1 in the disease
group compared to 1:2 in the treated group. Infiltration of T cells and CD18+ cells was reduced
approximately 50% after gene therapy.
Conclusion: We concluded that therapeutic levels of soluble TNF inhibitor were achieved in the
lacrimal gland and on the corneal surface. Anti-inflammatory cytokine gene expression might offer
a potential therapeutic modality for the treatment of autoimmune dacryoadenitis, once suitable
vectors become available.
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Background
Dry eye affects approximately 10 million Americans, most
of who are women. One of the most severe forms of dry
eye is found in Sjögren's syndrome patients. A combina-
tion of immunologic, genetic, hormonal, and environ-
mental factors may play a role in the development of
autoimmunity involving the lacrimal gland [1-3]. Lac-
rimal insufficiency is responsible for some severe forms of
dry eye and may be caused in part by lymphocytic infiltra-
tion. The inflammatory infiltrates produce toxic factors
that act as immune mediators, resulting in reduced secre-
tory function caused by secretory tissue atrophy and dys-
function of the surviving tissue [4,5].
Both murine and rabbit models have been used to eluci-
date the mechanisms of autoimmune lacrimal gland dis-
ease. Our Ocular Surface Center research group reported
that autologous peripheral blood lymphocytes (PBL) pro-
liferate when co-cultured with rabbit lacrimal gland epi-
thelial cells [6]. These activated lymphocytes induced
dacryoadenitis within 2 weeks when injected into the
donor rabbit's remaining contralateral gland, providing
an in vivo model of autoimmune dacryoadenitis [7,8].
The induced lacrimal gland dysfunction, characterized by
reduced basal tear production, reduced tear stability,
abnormal corneal surface staining, and increased presence
of CD4+ T cells, mimics several important features of kera-
toconjunctivitis sicca and Sjögren's syndrome.
Tumor necrosis factor (TNF)-α is a pro-inflammatory
cytokine produced mainly by monocytes and macro-
phages, although numerous other cells are also producers.
It is a pleiotrophic cytokine with two known receptors and
many regulatory effects, including cytotoxicity, anti-infec-
tion, growth modulation, and cellular differentiation.
Kolls et al. [9] produced a recombinant protein capable of
binding and neutralizing TNF and lymphotoxin. The
product, a fusion protein formed by joining the human
55-kDa TNF receptor extracellular domain to a mouse IgG
heavy chain, binds TNF by engaging two of its three recep-
tor sites. Kolls et al. [9] constructed an adenoviral vector
with a cytomegalovirus promoter encoding the chimeric
TNF inhibitor (AdTNFRIp55-Ig). Later, in a transplanta-
tion model, Ritter et al. (2000) [10] demonstrated that the
vector might be a useful gene therapy tool for controlling
inflammation. Using the same vector, we demonstrated
that expression of the TNF-inhibitor gene suppressed acti-
vation of lymphocytes by lacrimal epithelial cells in
mixed cell reactions [11].
Previously, in a prophylactic study utilizing the same clin-
ical parameters, we reported evidence that soluble TNF-
inhibitor protein partially suppresses the appearance of
Sjögren's syndrome-like features of reduced basal tear pro-
duction, as well as the immunohistopathology associated
with induced autoimmune dacryoadenitis [12]. The cur-
rent manuscript presents evidence that AdTNFRIp55-Ig
gene therapy treatment of rabbits with established
autoimmune dacryoadenitis results in improvement of
clinical features, such as an increase in basal tear produc-
tion, an increase in tear stability, and a reduction in sur-
face corneal defects. The therapy also reduced the
intensity of immune cell infiltration.
Methods
Animals, surgical procedures and clinical assessments
Female New Zealand white rabbits (3.5–4 kg) were
obtained from Irish Farms (Norco, CA). All animals were
used in accordance with the Association for Research in
Vision and Ophthalmology (ARVO) Resolution on Use of
Animals in Ophthalmic Research. Animals were main-
tained in a facility fully accredited by the American Asso-
ciation for Laboratory Animal Science. Clinical tests were
performed on all eyes prior to experimentation. The eyes
were initially examined by two investigators using slit-
lamp biomicroscopy, Schirmer testing after topical anes-
thetic eye drops (0.5% tetracaine), determination of tear
film breakup time (tear BUT), and rose bengal staining,
and no corneal defects were detected. Schirmer test paper
strips for measuring tear production were purchased from
Chauvin Pharmaceuticals Ltd (Romford, Essex, U.K.), flu-
orescein from Alcon Laboratories Inc, (Fort Worth, TX.)
and rose bengal strips from Akorn, Inc., (Abita Springs,
LA).
Results were recorded on a cornea diagram and scored
using a standardized grading system [13]. The intensity of
staining of the medial and lateral bulbar conjunctiva and
the cornea was graded; the maximum grade for each of
these three tests was 3, for a total maximum grade of 9 per
eye.
After anesthesia, the left lacrimal gland was surgically
removed from each rabbit for preparation of the purified
lacrimal gland epithelial cells (pLGEC) as previously
described [6,11]. Peripheral blood was also taken for lym-
phocyte preparation.
Cell culture and immunocytochemical reagents
Hepato Stim Culture Medium was purchased from Becton
Dickinson, (Bedford, MA). Ham's F12 medium and anti-
biotic/antimycotic mixtures were purchased from Gibco
BRL products, (Rockville, MD). Dulbecco's modified
Eagle's medium and fetal bovine serums were purchased
from Omega Scientific, (Tarzana, CA). Bovine serum albu-
min (BSA), soybean trypsin inhibitor, and linoleic acid
were purchased from Sigma Chemical Co., (St. Louis,
MO). Tritiated thymidine (3H-thymidine) was purchased
from DuPont NEN Research Products, (Wilmington, DE).
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were purchased from Spring Valley Labs, (Woodbine,
MD). Goat antiserum to rabbit T lymphocyte antigen
(RTLA) was obtained from Cedar Lane Laboratories
(Hornby, Ontario, Canada). Biotin-labeled goat anti-
mouse IgG Fc and donkey anti-goat IgG were purchased
from Chemicon International, (Temecula, CA). The
Vectastain Elite ABC kit was obtained from Vector Labora-
tories Inc., (Burlingame, CA). Propidium iodide was pur-
chased from Sigma (St. Louis, MO).
Autologous mixed cell reaction and induction of 
autoimmune dacryoadenitis
Descriptions of lacrimal gland excision, acinar cell purifi-
cation, and mixed cell reaction procedures have been pub-
lished previously [6,7,12]. Purified lacrimal gland
epithelial cells and PBL were isolated and cultured sepa-
rately for 2 days. Mixed cell reactions were performed
using equal numbers (1 × 106) of autologous PBL and
2500 RAD γ-irradiated pLGEC, then co-cultured for 5
days. The cells were also cultured in 96-well plates under
the same conditions, but using 1 × 105 cells of each type
to monitor PBL proliferation. The cells were incubated
with 1 µ Curie of 3H-thymidine and harvested 24 hr later
using a Brandel model 290 PHD™ sample harvester
(Gaithersburg, MD). An LS 6000IC beta scintillation
counter (Beckman Instruments, Inc., Fullerton, CA) was
used to measure 3H-thymidine incorporation. A mini-
mum of 6 wells was counted to obtain representative data.
Peripheral blood lymphocytes from mixed cell reactions
with a stimulation index greater than 2 were considered to
contain activated lymphocytes and, therefore, to be suita-
ble for the induction of dacryoadenitis.
Two million stimulated lymphocytes were injected into
the central region of the inferior lacrimal glands of the
right eyes of the respective donor rabbits using a 25-gauge
butterfly needle on a tuberculin syringe. To avoid tissue
damage caused by rapid volume expansion, the micro-
volume delivery system was set to deliver 10 µl at 10-sec
intervals (10 µL × 20 repetitions = 200 µL). Rabbits receiv-
ing stimulated cells from the mixed cell reaction are here-
after referred to as induced dacryoadenitis (ID) animals.
Vectors and in vivo transduction
An adenovirus construct carrying the TNF-inhibitor gene
(AdTNFRp55-Ig) described previously was used [9,10].
Briefly, a fusion protein was formed by joining the human
55-kDa TNF receptor (TNFRp55) extracellular domain
with a mouse IgG heavy chain (TNFRp55-Ig) for stability.
It was then subcloned into the pACCMV vector to gener-
ate recombinant Ad expressing the TNFRp55-Ig chimeric
molecule. This Ad vector, which had a promoter from the
human cytomegalovirus, expressed soluble TNFRp55-Ig
that had the ability to completely block TNF-α and lym-
photoxin-α. Half of the ID animals described above were
transduced with AdTNFRp55-Ig (1 × 108 pfu in 0.2 ml
injected into each lacrimal gland after clinical symptoms
showed established disease. These animals are hereafter
referred to as ID/treated or ID/AdTNFRI). There were 5 or
more animals in each study group.
Tissue collection and immunohistopathology
All animals were sacrificed at the end of 4 weeks (i.e. week
4 was 2 weeks after gene therapy). Inferior lacrimal glands
of the right eyes were excised and dissected longitudinally
into two parts. One part was fixed in 10% formalin and
embedded in paraffin; the second part was embedded in
optimal cutting temperature (OCT) compound (Miles,
Inc., Elkhart, NJ), then snap-frozen in liquid nitrogen and
stored at -70°C until histologic examination. Cryosec-
tions of the transduced tissues were fixed in 4% parafor-
maldehyde, then counterstained with propidium iodide
(50  µg/ml). A minimum of 5 fields were randomly
selected and photographed with a confocal microscope
for cell analysis. The paraffin-embedded tissue samples
were sectioned at 5 µm, then deparaffinized and stained
with hematoxylin and eosin (H&E) for light microscopic
examination. The OCT-embedded tissue samples were
also sectioned at 5 µm using a cryostat, fixed in chilled
acetone (4°C), air-dried, then rehydrated in phosphate-
buffered saline for immunohistologic staining. After the
sections were blocked with 5% BSA for 15 min, they were
incubated either at room temperature for 1 hr or in a
humidified chamber at 4°C overnight with primary anti-
bodies: mouse anti-CD18 (1:1000), goat anti-RTLA
(1:300), CD4, or CD8 (1:200). The sections were then
incubated with biotinylated species-specific secondary
antibody for 60 min at room temperature. The sections
were rinsed again, then quenched with 0.3% H2O2 in 40%
methanol for 15 min, incubated in ABC reagent for 30
min, rinsed three more times, then developed for 3 min.
Negative controls were performed for each antibody using
1% normal sera from the same species that the primary or
secondary antibodies were derived from as substitutes for
either primary or secondary incubation. Hematoxylin
counterstain was applied before mounting. Cells that
stained positive exhibited an intense brown color and
were readily distinguished from the blue background. The
entire section was scanned and analyzed with an Auto-
mated Cellular Imaging System (ACIS®: ChromaVision
Medical Systems, Inc., San Juan Capistrano, CA). ACIS, a
proprietary, color-based imaging technology with auto-
mated microscopy, provides quantitative data, including
percent positive, intensity scoring, and area measurement.
ChromaVision system is designed to measure the total
area occupied by all cells in a scanned section and the per-
centage of that area that is occupied by cells expressing a
specific cell marker for CD4, CD8, CD18, or RTLA. Four
sections from each gland were scanned for a total of 20Journal of Autoimmune Diseases 2005, 2:6 http://www.jautoimdis.com/content/2/1/6
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scanned sections per group. Data are shown as mean pos-
itive percentage ± SD.
Statistics
Data collected from clinical analysis and ChromaVision
were subjected to paired t-test or signed rank sum test and
analysis of variance (ANOVA). Multiple comparison t-
tests were calculated when ANOVA p ≤ 0.05. Statistical sig-
nificance was adjusted for the number of pairwise com-
parisons with a Bonferroni correction.
Results
Induced autoimmune dacryoadenitis and clinical 
assessment
Autologous PBL, activated by co-culture with rabbit lac-
rimal gland epithelial cells, induced dacryoadenitis within
2 weeks when injected into the donor rabbit's remaining
contralateral lacrimal gland. Clinical assessments, includ-
ing basal tear production (Fig. 1), tear breakup time (Fig.
2) and rose bengal staining (Fig. 3) were performed on 10
rabbits at 0, 2 and 4 weeks after induction of disease.
Before disease induction, the Schirmer test scores based
on 1 min readings, representing normal basal tear produc-
tion for the two study groups were 7.6 to 7.1 mm (Fig. 1).
Two weeks after disease induction, tear production
dropped more than 40% to scores of 4.5 and 4.0, respec-
tively. The lacrimal glands of animals in one group were
then transduced with AdTNFRp55-Ig; clinical assessment
tests were repeated 2 weeks later. Schirmer scores for the
gene therapy group (ID/treated) increased to 8.1 mm,
indicating improved tear secretion, while Schirmer scores
for the untreated disease group (ID) decreased to 3.9 mm.
Before disease induction, tear BUT was 20 sec. Two weeks
after disease induction, tear BUT decreased to11.3 and
10.1 sec, indicating a loss of tear stability for both groups.
Basal tear production was measured by Schirmer test in 10 rabbits (0 w) Figure 1
Basal tear production was measured by Schirmer test in 10 rabbits (0 w). Dacryoadenitis was induced in these rab-
bits using lymphocytes activated in a mixed cell reaction. These rabbits were designated the induced dacryoadenitis (ID) group. 
At 2 w and 4 w, tear production in the ID group was significantly reduced (p = 0.005 and 0.006, respectively) compared to tear 
production at 0 w. The Schirmer test was repeated at 2 w for those animals to be treated; tear production was significantly 
reduced (p = 0.04) compared to at 0 w. At 2 w, 5 of the 10 ID animals received an injection of 1 × 108 pfu of AdTNFRp55-Ig 
into the remaining lacrimal gland. These animals were designated the ID/AdTNFRI treatment group. At 4 w (2 w after treat-
ment) tear production was remeasured. There was no significant difference in tear production in the treatment group at 4 w 
compared to at 2 w (p = 0.52); however, there was a significant difference in tear production between the treated and 
untreated groups at 4 w (p = 0.04).
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Four weeks after disease induction, tear BUT for the
treated group was closer to normal (16.2 sec) while in the
untreated group, tear stability remained unchanged (10.2
sec).
Rose bengal staining scores before disease induction
started at 0.2 and increased to 2.6 for both groups at 2
weeks. At 4 weeks, scores for the treated group decreased
to 1.6 while scores for the untreated group continued to
increase (3.4).
Immune cell infiltrates
Microscopic examination of H&E-stained normal lacrimal
gland (Fig. 4A) revealed sparsely scattered lymphocytes,
plasma cells, and macrophages located throughout the
gland. Glands from animals with induced dacryoadenitis
(without and with treatment in Fig. 4B and 4C, respec-
tively) contained immune cell infiltrates, consisting of
small to large foci that stained positive for CD4 (Fig. 4D
and 4E, respectively), CD8 (Fig. 4F and 4G, respectively),
RTLA (Fig 4H and 4I, respectively), and CD18 (Fig 4J and
4K, respectively) antigens located between acini and
around ducts and venules. Occasionally, CD8+ cells were
seen within acinar and ductal epithelium, and some areas
had atypical acinar morphology.
Table 1 provides a summary of the quantitative analysis of
CD4+, CD8+, RTLA+, and CD18+ immune cells present in
lacrimal gland tissue. In normal tissue, the ratio of CD4+
to CD8+ stained area was approximately 1:1.4 (0.34%
and 0.49% of the stained area was occupied by CD4+ and
CD8+ T cells, respectively). Four weeks after disease
induction, the ratio changed to about 3:1 (i.e. 1.20% and
0.47% as explained above). In the normal lacrimal gland
sections, 1.65% of the area was RTLA+ and 0.17% was
CD18+. Four weeks after disease induction, there was a
significant increase of RTLA+ and CD18+ cells in the lac-
rimal tissue (13.2% for RTLA+ and 9.68% for CD18+
cells). After gene therapy, the numbers of CD4+, RTLA+
and CD18+ cells declined, and the CD4:CD8 ratio
reverted to 1:2 (0.8% and 1.63%, respectively). Compared
to ID group, significant decrease of CD4+, RTLA+ and
Tear break-up time (BUT) was measured at 0 w, 2 w, and 4 w Figure 2
Tear break-up time (BUT) was measured at 0 w, 2 w, and 4 w. In the ID group, tear BUT was significantly decreased 
at 2 w and 4 w compared to at 0 w (within group comparison p = 0.0002). Tear BUT was significantly different for the ID/AdT-
NFRI group (p = 0.002) at 2 w, before treatment, but not at 4 w, after treatment (p = 0.09). A between groups comparison (ID 
and ID/AdTNFRI) revealed a significant difference only at 4 w (p = 0.005).
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CD18+ cells was found in AdTNFRI treated lacrimal
glands (p < 0.001), whereas CD8+ cells increased signifi-
cantly following gene therapy (p < 0.0001).
Discussion
The lacrimal glands produce most of the fluid that is
essential for keeping the ocular surface tissue healthy and
for maintaining a smooth refractive interface for light
entering the eye. Lacrimal insufficiency can result from
both immune and nonimmune mechanisms. In our ani-
mal model of autoimmune dacryoadenitis, activated
autologous lymphocytes trigger a lymphocytic infiltration
that impairs glandular function, mimicking Sjögren's syn-
drome. In this system, the lacrimal gland epithelial cells
become dysfunctional, resulting in reduced tear produc-
tion and a loss of tear stability [12].
In a previous in vitro gene transfer study, we reported
transducing cultured lacrimal gland epithelial cells with
adenovectors carrying a TNF-inhibitor gene, TNFRp55-Ig
[11]. Expression of the transgene in these cells suppressed
their ability to activate lymphocytes in a mixed cell reac-
tion. The soluble TNF-inhibitor gene product was present
in the culture media of the transduced cells for up to 4
weeks. In a later study involving the in vivo transduction
of the lacrimal gland with the same vector, the soluble
TNF receptor transgene protein was detectable in tears
after 7 days, but not at 14 days [8]. This transient expres-
sion is a well-known feature of adenovirus-mediated gene
transfer and is thought to be a consequence of nonintegra-
tion of the transgene DNA into the cell genome and pos-
sibly the elimination of transduced cells by the immune
system. In spite of this transient gene expression, there
was a beneficial impact on the induced disease. Basal tear
production, tear stability, and ocular surface defects, three
common clinical parameters that are used to diagnose dry
eye [1], were improved. Without treatment, tear produc-
tion and tear BUT declined by about 45% to 50%, and
ocular surface damage increased by 60%, based on a scor-
ing system for rose bengal staining that has high sensitiv-
ity and specificity for surface defects. The intensity of
immune cell infiltration in the lacrimal gland also
declined.
Adenovirus vectors used in gene therapy can elicit an
immune response in the recipient. Previously, we
Deficiency in preocular tear film protection was determined with rose bengal stain; the ID group was compared to the ID/ AdTNFRI group Figure 3
Deficiency in preocular tear film protection was determined with rose bengal stain; the ID group was com-
pared to the ID/AdTNFRI group. Staining at 2 w and 4 w was significantly different from at 0 w (p = 0.001 and 0.002, 
respectively) within the ID group, as well as within the ID/AdTNFRI group (p = 0.001 and 0.006, respectively). A between 
groups comparison (ID versus ID/AdTNFRI) revealed a significant difference only at 4 w (p = 0.0008).
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Hematoxylin & eosin stained lacrimal sections from animals designated normal (A), ID (B), and ID/AdTNFRI (C) Figure 4
Hematoxylin & eosin stained lacrimal sections from animals designated normal (A), ID (B), and ID/AdTNFRI 
(C). (Bar, 40 µm). Immunohistochemical staining of ID and the diseased treated group ID/AdTNFRI cryosections (Bar, 20 µm) 
for CD4 (D) and (E), respectively; for CD8 (F) and (G), respectively; for RTLA (H) and (I), respectively; for CD18 (J) and (K), 
respectively.Journal of Autoimmune Diseases 2005, 2:6 http://www.jautoimdis.com/content/2/1/6
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reported that our adenovirus vector, expressing the green
fluorescent protein (GFP) gene using the same CMV
promoter as in AdTNFRp55-Ig, induced similar numbers
of CD4+ and CD8+ T cells to what is found in normal
nontransduced glands, although numbers of RTLA+ and
CD18+ cells present in lacrimal tissue did increase follow-
ing transduction [8].
We also reported that reduced tear production and tear
break-up time was detectable 2 weeks after induction of
dry eye disease and that these clinical features persisted for
at least 6 more weeks on our model [12]. For this current
study, we elected to intervene therapeutically after acute
disease was recognizable (i.e. 2 weeks after initiating dis-
ease) and to evaluate short-term gene therapy treatment at
4 weeks knowing that adenovirus-mediated TNF-inhibi-
tor transgene expression would be less than 2 weeks in our
system [8]. In the current studies we demonstrated that
even transient expression of the TNF-inhibitor gene in the
lacrimal tissue has a desirable impact on clinical and path-
ological features of established autoimmune dacryoaden-
itis. For future studies, it would seem that a long-term
transgene expression would be appropriate; therefore our
follow-up study will test long-term expression using an
AAV vector carrying the TNF-inhibitor gene.
Conclusion
Adenovirus-mediated transfer of the TNFRp55-Ig gene to
the lacrimal gland resulted in expression of the transgene
product and its secretion into tears. The presence of the
TNF inhibitor protein in the lacrimal gland promoted
recovery of tear production and tear stability and reduced
immunopathology in rabbits with established autoim-
mune dacryoadenitis. It appears that severe dry eye may
benefit by down regulating TNF.
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